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Autophagy refers to an essential mechanism that evolved to sustain eukaryotic homeostasis and 
metabolism during instances of nutrient deprivation. During autophagy, intracellular cargo is 
encapsulated and delivered to the lysosome for elimination. Loss of basal autophagy in vivo 
negatively impacts cellular proteostasis, metabolism and tissue integrity. Accordingly, many drug 
development strategies are focused on modulating autophagic capacity in various 
pathophysiological states, from cancer to neurodegenerative disease. The role of autophagy in 
cancer is particularly complicated, as either augmenting or attenuating this process can have 
variable outcomes on cellular survival, proliferation and transformation. This complexity is 
compounded by the emergence of several selective autophagy pathways, which act to eliminate 
damaged or superfluous cellular components in a targeted fashion. The advent of sensitive tools to 
monitor autophagy pathways in vivo holds promise to clarify their importance in cancer 
pathophysiology. In this review, we provide an overview of autophagy in cancer biology and 
outline how the development of tools to study autophagy in vivo could enhance our understanding 
of its function for translational benefit. 
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Autophagy is an essential catabolic mechanism that evolved to sustain eukaryotic homeostasis 
during instances of nutrient deprivation. The term autophagy is translated from the Greek meaning 
"to eat oneself" and interestingly, was in usage before its incorporation into the scientific vernacular 
by Christian De Duve (Ktistakis, 2017). General or bulk autophagy is a non-selective process 
(herein referred to as macroautophagy) (Zachari and Ganley, 2017). Macroautophagy is a complex, 
multistep process involving (1) the sensing and identification of cellular cargo for destruction, (2) 
marking this cargo for recognition by the autophagy machinery, followed by (3) its encapsulation 
within a transient double membrane-bound organelle known as an autophagosome and (4) 
elimination of the sequestered contents via fusion of the autophagosome with an acidic 
compartment of the endolysosomal system, resulting in the formation of the autolysosome 
(Mizushima, 2018). This process results in the recycling of autophagic substrates, which is thought 
to fuel various metabolic pathways (White, 2015). Autophagy is an evolutionarily conserved 
process that is also essential for mammalian development. Impaired autophagic activity (termed 
"flux") is detrimental to cell and tissue function. Because of its links to organismal longevity, 
homeostasis and metabolism, autophagy has evolved to become an attractive therapeutic target for a 
variety of clinical indications (Galluzzi et al., 2017b). Indeed, dysregulated autophagic flux has 
emerged as a stand-alone hallmark of mammalian cancer (Hanahan and Weinberg, 2011). 
Recognising its vital biomedical importance, Professor Yoshinori Ohsumi received the 2016 Nobel 
Prize in Physiology or Medicine for pioneering the molecular basis of autophagy (Mizushima, 
2017). Treatments that modulate autophagic capacity are widely thought to represent a 
therapeutically advantageous strategy to prevent cancer development (Mizushima, 2018). As we 
will see in this review, understanding autophagy presents a challenging conundrum in the context of 
cell transformation, cancer biology and chemoresistance. We summarise critical concepts related to 
our current knowledge of physiological autophagy pathways and their relationship to cancer 
biology. In particular, we discuss how developments that enable researchers to monitor autophagy 
pathways in vivo could clarify mechanistic questions of outstanding translational importance. 
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The modern-day definition of autophagy broadly encompasses two sub-phenomena: 
macroautophagy and selective autophagy (Mizushima, 2018). The cargo to be degraded can vary 
from organelles, and proteinaceous aggregates to ferritin, lipids and carbohydrates. 
Macroautophagy is by far the best-studied autophagy pathway and refers to a non-selective or bulk 
digestion process, induced by many signals and stimuli (Zachari and Ganley, 2017). The most well-
described induction stimulus in mammals is nutrient deprivation, resulting in the inhibition of the 
master nutrient sensor mTORC1 (Laplante and Sabatini, 2012). However, work by the laboratory of 
Terje Johansen has recently redefined the temporal dynamics of the autophagic response to amino 
acid deprivation (Mejlvang et al., 2018). Loss of GSK3-beta signalling is also associated with the 
initiation of macroautophagy, in addition to activation of AMPK and HIF signalling (Lin et al., 
2012). The initiation and progression of autophagosome biogenesis involve the activation of 
autophagy-specific kinase complexes ULK1 (comprised of ULK1/2, FIP200, ATG101, ATG13), 
and VPS34 (including BECLN1) as well as the ATG16L1-ATG5-ATG12 conjugation machinery 
(Xie and Klionsky, 2007; Zachari and Ganley, 2017). The exact membrane origin or source that 
contributes to the nucleation of the transient autophagosome has been a controversial topic in the 
field for many years. However, a growing consensus suggests a multi-organellar contribution to 
autophagosome biogenesis, with subdomains of the endoplasmic reticulum (ER), ER and Golgi 
intermediate compartment (ERGIC), mitochondria and endolysosomal system playing key roles 
here (Bissa and Deretic, 2018; Ge et al., 2013; Hailey et al., 2010). ATG9A and ATG2 have both 
recently been reported to transport lipids to promote autophagosome formation (Valverde et al., 
2019). Autophagosome closure and maturation constitutes a critical step that precedes 
autolysosome formation, yet we know less about its molecular regulation compared to upstream 
initiation events. It has been hypothesised that autophagosome sealing resembles a membrane 
scission event (Zhou et al., 2019). The budding yeast Saccharomyces cerevisiae has enabled the 
detailed study of these discrete steps at an unparalleled resolution, with recent work implicating the 
Rab5-dependent recruitment of ESCRT machinery in the closure of unsealed autophagosomes 
(Zhou et al., 2019). COPII-coated carriers ensure transport between the ER and Golgi complex and 
have also been shown to contribute to autophagosome membrane formation in yeast (Shima et al., 
2019). Figure 1 provides a clear graphical overview of macroautophagy.  
 
Textbook autophagosomes are classically depicted as single spheroids, yet advances in electron 
tomography have revealed the presence of multiple smaller vesicles of unknown function that are 
juxtaposed to mature autophagosomes (Biazik et al., 2015). The steps of cargo recognition, 
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the ATG8 family of proteins (LC3A/B/C, and GABARAP/GABARAPL1/2) (Bissa and Deretic, 
2018; Ganley, 2013). The end stage of all autophagy pathways depends on functional acidic 
compartments of the endolysosomal system to degrade the encapsulated cargo. A lysosome fuses 
with an autophagosome to form an "autolysosome", or an acidic Rab5/7-positive late endosome can 
fuse with an autophagosome to generate an "amphisome". An informative primer on autophagy 
nomenclature can be found in (Klionsky et al., 2014). The process of autophagosome-lysosome 
fusion is mediated by two independent autophagosomal SNARE protein complexes, syntaxin 17 
and YKT6 (Matsui et al., 2018; Itakura et al., 2012).  
 
Our understanding of the lysosome as a simple "suicide bag" has been dramatically revised by 
discoveries of its nutrient sensing properties in mammalian cells (Lim and Zoncu, 2016). 
Lysosomes orchestrate critical aspects of cellular metabolism, and also appear to be more 
phenotypically heterogeneous than previously thought. Recent findings demonstrate that lysosomes 
in distinct spatial cellular compartments are differentially acidic (Johnson et al., 2016), indicating 
that their function likely extends beyond mere digestion. This conceptional evolution in our 
understanding of the lysosome also necessitates a more in-depth evaluation of how nutrient status 
modulates crosstalk between autophagic compartments and the endolysosomal system.  
 
The degradation of autophagic substrates acts to replenish amino acids necessary for protein 
synthesis and cellular homeostasis. This step of the pathway is associated with the reactivation of 
mTOR and a process known as autophagosome-lysosome reformation (ALR) (Chen and Yu, 2013). 
ALR is a terminal event that promotes lysosomal reformation from autolysosomes via membrane 
tubulation and scission. Ultimately, ALR sustains cellular lysosomal homeostasis during and after 
autophagy (Chen and Yu, 2013).  A key regulator of this process is lysosome-associated PI(3)P, 
generated by the VPS34–UVRAG complex in an mTOR-dependent fashion (Munson et al., 2015). 
  
Autophagy may also occur in the absence of canonical factors. A Rab9-pathway has been suggested 
to sustain autophagy in the absence of ATG5/ATG7/LC3-II (Nishida et al., 2016). Tripartite motif 
(TRIM31), an intestine-specific protein localised in mitochondria has also been implicated in 
Atg5/7-independent autophagy in gastrointestinal cells (Ra et al., 2016). In recent years, autophagy-
independent functions of the ATG machinery have also manifested. Please consult (Galluzzi and 
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In addition to non-selective macroautophagy, it is now well-established that autophagy can also be 
highly selective (Mizushima, 2018). Selective autophagy refers to the targeted destruction of 
damaged or superfluous cellular components. Cargo-specific autophagy receptors confer selectivity 
on various cellular constituents from organelles (organellophagy) to proteinaceous aggregates 
(aggrephagy) (Okamoto, 2014). Selective autophagy is a fast-moving domain of the field and 
involves an interplay between the post-translational modifications ubiquitylation and 
phosphorylation (Khaminets et al., 2016). The best-studied selective autophagy pathway to date is 
mitochondrial autophagy (mitophagy); however, pexophagy (Marcassa et al., 2018), ribophagy 
(Wyant et al., 2018) and ferritinophagy (Santana-Codina and Mancias, 2018) are also emerging as 
important determinants of cellular homeostasis. The following reviews provide a comprehensive 
overview of selective autophagy (Rogov et al., 2014; Galluzzi et al., 2017a). Reconciling the 
interplay between stimulus-induced and basal physiological autophagic turnover in vivo constitutes 
a significant challenge in the field (See section 4 for a discussion of selective autophagy).  
 
Independently of the aforementioned pathways, chaperone-mediated autophagy (CMA) constitutes 
a distinct form of selective autophagy (Kaushik and Cuervo, 2018). The cytosolic chaperone 
HSC70 recognises protein substrates containing a distinct CMA-targeting motif (KFERQ) and 
targets these to the lysosomal surface, where they undergo active translocation via LAMP-2A 
(Kaushik and Cuervo, 2012, 2018). Levels of lysosomal LAMP-2A reflect the activity of CMA. 
Pioneering work by Ana Maria Cuervo and colleagues has demonstrated the critical importance of 
CMA in mammalian health and disease. Please consult (Kaushik and Cuervo, 2018) for a 
comprehensive overview of CMA.  
 
3. Autophagy in cancer: a complex conundrum united by metabolic crosstalk 
 
Autophagy is a disease-relevant process, yet it remains controversial whether dysregulated flux is a 
cause or consequence of any human disorder. From our perspective, the most accurate, evidence-
based interpretation is that the role of autophagy in any physiological or pathological scenario 
appears to be highly context-dependent. This complexity becomes especially apparent when 
considering the astounding mechanistic heterogeneity of cancer. Accordingly, enhanced autophagy 
can either drive or diminish tumourigenesis depending on the cellular state and tissue type (Galluzzi 
et al., 2017b).   
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Insights from cell culture and pre-clinical animal studies have demonstrated that autophagy sustains 
tissue homeostasis and prevents pro-oncogenic environments through interplay with genome 
stability and anti-inflammatory signalling pathways (Amaravadi et al., 2016; Mathew et al., 2009).  
 
Although core autophagy genes are not generally mutated in human cancers, polymorphisms and 
altered expression levels of autophagy-related proteins have been reported (Jiang and Mizushima, 
2014). Additionally, autophagy genes have been implicated as both tumour enhancers and 
suppressors (White, 2015). Valuable insights into the role of autophagy in human oncology came 
from the discovery that the autophagy modulator Beclin-1 (BECN1) is lost in a substantial 
proportion of human breast, ovarian and prostate cancers (Liang et al., 1999; Yue et al., 2003; Qu et 
al., 2003). 
 
Consequently, human BECN1 has been proposed as a haploinsufficient tumour suppressor gene. 
Consistent with this, heterozygote Becn1 mice exhibited enhanced susceptibility to hepatic, 
mammary and lymphoid neoplasia (Qu et al., 2003). BECN1 exerts critical cellular functions, 
although its role as a bona fide tumour suppressor appears somewhat contentious in the field (White 
et al., 2015). Recently, an interesting study focused on abolishing the interaction of endogenous 
Beclin-1 with the negative regulator of Beclin-1-dependent autophagy Bcl-2 (Pattingre et al., 2005) 
in vivo, via the generation of knock-in mice with a constitutively active variant of Beclin-1 
(Becn1F121A/F121A). Tissues from Becn1 mutant animals exhibit enhanced levels of autophagic flux 
coupled to improvements in healthspan, longevity and a diminished incidence of age-related 
spontaneous cancer (Fernández et al., 2018). In another study, endogenous HER2 was reported to 
interact with Beclin-1 to inhibit autophagy and drive tumourigenesis. The enhanced levels of basal 
autophagy in Becn1F121A mice also had an anti-tumourigenic influence on HER2-mediated cancer 
progression (Vega-Rubín-de-Celis et al., 2018). Treatment of mice harbouring HER2-breast cancer 
xenografts with an autophagy-inducing peptide (Tat-Beclin-1) diminished tumour growth in vivo 
and could represent an attractive therapeutic approach for HER2-positive breast cancer (Vega-
Rubín-de-Celis et al., 2018). Interestingly, another autophagy regulator, UVRAG (described earlier 
for its role in ALR) is found to be mutated in colon cancer and is also proposed to be a 
haploinsufficient tumour suppressor (Liang et al., 2006). 
 
Loss of autophagy is increasingly associated with the initiation of cancer. To this effect, autophagic 
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a process termed replicative crisis. During replicative crisis, pre-cancerous cells with dysregulated 
cell cycle checkpoints undergo continual division, leading to progressive telomeric DNA shortening 
and apoptosis. Cells that bypass this senescence-independent process harbour high levels of 
chromosomal instability and exhibit an increased propensity for oncogenic transformation, 
suggesting that replicative crisis is an essential anti-cancer mechanism (Nassour et al., 2019).  
Nassour et al. discovered that autophagy-deficient cells with deregulated cell cycle checkpoints 
could evade both crisis and cell death, and ultimately accrue chromosomal instability. Telomeric 
DNA damage generates cytosolic chromatin fragments that specifically activate cGAS-STING 
(cyclic GMP-AMP synthase-stimulator of interferon genes) signalling and the recruitment of the 
autophagy machinery (Nassour et al., 2019). These data suggest that cell death in replicative crisis 
is associated more with autophagy rather than canonical apoptosis. Overall, these findings highlight 
the protective nature of autophagy and raise potential caveats when considering its therapeutic 
inhibition in cancer. 
 
Pre-clinical studies of cancer in mice have shown that loss of essential autophagy genes promotes 
tumourigenesis, and thus, the presence of functional autophagy in these contexts seems to be anti-
oncogenic. Furthermore, the severity of tumourigenesis seems to be associated with oncogenic 
background and cellular context. To this effect, conditional hepatic ablation of Atg5 leads to 
hepatotoxicity, inflammation and the development of benign liver tumours in mice (Takamura et 
al., 2011). Similar conditional experiments show that autophagy also exerts protective effects in the 
pancreas (Rosenfeldt et al., 2013). In pancreatic cancer characterised by mutant Kras, loss of 
pancreatic autophagy drives oncogenesis, yet malignancy appears to be restricted here (Yang et al., 
2014). Furthermore, genetic ablation of essential autophagy genes induces the accumulation of the 
autophagy adapter protein p62 (SQSTM1), which is also thought to promote tumourigenesis (Wei 
et al., 2014).   
 
Genetic inhibition of autophagy in a humanised mouse model of pancreatic ductal adenocarcinoma 
(PDAC; activated oncogenic Kras, p53 KO double-mutant) is associated with an unfavourable 
prognosis. PDAC is a notoriously lethal cancer, characterised by high mortality and low survival 
rates (National Cancer Institute., 2018). PDAC mice with impaired autophagy (lacking Atg5 or 
Atg7) exhibited accelerated tumour onset coupled with a metabolic state conducive to 
tumourigenesis (enhanced glucose uptake and anabolism) (Rosenfeldt et al., 2013). In another 
PDAC model driven by oncogenic KRAS (G12D) combined with ablation of the tumour suppressor 
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development. These findings suggest that both p53 and PTEN can influence the contribution of 
autophagy to PDAC and reflects the context-dependent nature of this problem (Rosenfeldt et al., 
2017). Treatment of Kras p53 double KO mice with hydroxychloroquine (HCQ; an agent known to 
impair autophagy) was shown to enhance tumourigenesis. These data are pertinent due to the use of 
HCQ as an anticancer agent in clinical trials and highlight the need for studying drug treatments in 
cellular contexts that closely recapitulate the human condition (Rosenfeldt et al., 2013). Please 
consult Mainz and Rosenfeldt for an authoritative review on the study of autophagy in pre-clinical 
mouse models of cancer (Mainz and Rosenfeldt, 2018). 
 
3.2 The pathological influence of autophagy in cancer 
 
Conversely, cancer cells can also use autophagy to their pathological advantage. 95% of PDACs 
arise from activating KRAS mutations and have been linked with autophagy-dependent 
tumourigenic growth (Viale et al., 2014). Therefore anti-KRAS and anti-autophagy therapies, in 
general, have emerged as attractive strategies to treat PDAC (Viale et al., 2014). Chronic KRAS 
inhibition in PDAC mouse cell lines revealed a rare subpopulation of dormant tumour cells that can 
drive tumour relapse. These resistant cells survive oncogene ablation, become increasingly 
dependent on autophagy and exhibit a bioenergetic preference for mitochondrial respiration 
(oxidative phosphorylation) over glycolysis (Viale et al., 2014). 
 
Furthermore, Bryant and colleagues demonstrated that KRAS inhibition enhances autophagic flux 
in human and mouse PDAC cell lines (Bryant et al., 2019). Acute ablation of mutant KRAS or 
selective ERK inhibition in PDAC cells both resulted in the same metabolic effect by increasing 
autophagic activity at multiple levels (enhanced autophagosome flux, phosphorylation and 
activation of AMPK and Beclin-1, downregulation of mTOR signalling, and increased transcription 
of autophagy-related genes). In addition to enhanced autophagic flux, both ERK inhibition and 
KRAS silencing also influenced metabolic state, evidenced by diminished glycolysis and altered 
mitochondrial function. Bryant et al. demonstrated that combinational therapy targeting the 
increased autophagy and increased ERK activity is an effective treatment against KRAS driven 
PDAC in mice (Bryant et al., 2019; Kinsey et al., 2019). These data highlight the complex interplay 
between autophagy, metabolism and cancer progression. For an excellent overview of autophagy 
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Cancer cells also have increased metabolic requirements to support their accelerated growth 
(Rabinowitz and White, 2010). The microphthalmia/transcription factor E (MIT/TFE) family of 
transcription factors regulate energy metabolism by controlling the expression of genes that regulate 
both autophagy and lysosomal biogenesis. These factors also have established roles in promoting 
tumourigenesis (Perera et al., 2015; Kauffman et al., 2014) and have been reviewed recently in 
(Perera et al., 2018). 
 
3.3 Autophagy as a therapeutic target in cancer  
 
The clinical benefit of autophagy inhibition in human cancer remains controversial (Mainz and 
Rosenfeldt, 2018). Nonetheless, clinical trials aiming to modulate levels of autophagy in cancer are 
underway (Levy et al., 2017a).  To date, chloroquine (CQ) and its derivative HCQ are the only 
repurposed drugs used in the clinic to inhibit autophagic flux and are already approved to treat 
malaria. CQ and HCQ have been associated with favourable clinical outcomes for cancer therapy 
(Levy et al., 2017a). CQ was first tested on 18 glioblastoma patients and showed positive results, 
increasing survival from 11 to 33 months when combined with radiation therapy and the alkylating 
agent, temozolomide (Briceño et al., 2003). Follow up studies verified the benefits of CQ in 
improving survival of glioblastoma patients (Briceño et al., 2007; Sotelo et al., 2006).  HCQ has 
been used in various clinical trials involving different malignancies, with therapeutic dosage 
determined by the cancer subtype and pre-existing treatment regimen (Rangwala et al., 2014b; a). 
Results from these trials have been varied, with HCQ treatment exerting little effect on patient 
health compared to controls (Rosenfeld et al., 2014; Goldberg et al., 2012; Mahalingam et al., 
2014). Furthermore, CQ was also shown to sensitise cancer cells to chemotherapy through 
autophagy-independent mechanisms. Thus, it is necessary to consider that the effects of 
CQ/HCQ may occur independently of direct flux inhibition (Maycotte et al., 2012). 
 
Accordingly, although lysosomotropic drugs such as HCQ attenuate autophagic flux, these 
compounds have been reported to activate a parallel noncanonical autophagy pathway that drives 
LC3 lipidation on endosomal membranes (Jacquin et al., 2017). Nonetheless, CQ and HCQ 
treatment undoubtedly compromise autophagic flux in vitro. However, readers should be aware that 
recent mechanistic insights have emerged comparing CQ to other lysosomal inhibitors such as 
Bafilomycin A1. CQ and HCQ inhibited autophagy by impairing autophagosome-lysosomal fusion, 
rather than by affecting the acidity and degradative activity of the autolysosome. CQ/HCQ 
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intestinal and kidney cells (Mauthe et al., 2018). These findings merit vital mechanistic 
consideration when interpreting and evaluating autophagy-associated compounds as precision 
therapeutics for cancer. As outlined in section 2, autophagy is a multistep pathway with several 
nodes representing attractive targets for drug discovery (e.g. inhibitors of ULK1/2, ATG4B, p62). 
At present, vital tool compounds exist, but their utility in disease models remains to be determined. 
Please consult (Limpert et al., 2018) for an up-to-date overview of small molecule modulation of 
autophagy in cancer. 
 
A large number of studies have shown that cancer cell subtypes respond differentially to autophagic 
inhibition. To this effect, RNAi-based studies in various breast cancer cell lines revealed a 
differential dependency on autophagy for proliferation and survival (Maycotte et al., 2014). In 
cancer subtypes where autophagy is dispensable for survival, autophagy inhibition may have only a 
modest effect. Accordingly, the degree of autophagy inhibition required for therapeutic efficacy 
may vary depending on its combination with a given chemotherapeutic strategy. In order to 
integrate autophagy therapeutics as part of a meaningful precision medicine approach, it will be 
necessary to devise standardised clinical protocols that incorporate the autophagy-dependence of 
cancer subtypes for predicted patient benefit. For a detailed overview of autophagy therapeutics and 
clinical trials in cancer, please refer to the excellent review by Mulcahy Levy and colleagues (Levy 
et al., 2017a).  
 
In BRAF-mutant melanoma, therapeutic inhibition of BRAF acts to increase autophagy (Ma et al., 
2014), and thus combination therapies targeting the increased autophagy as well as BRAF 
inhibition are proposed to combat tumourigenesis (Levy et al., 2017b; Wang et al., 2017).  
 
Autophagy also influences the survival of dormant breast cancer cells and metastatic tumour 
reoccurrence (Vera-Ramirez et al., 2018). Pharmacogenetic experiments demonstrated an essential 
role for ATG7 in this context, with selective inhibition of autophagic flux in dormant breast cancer 
cells showing promise as a potential anti-cancer strategy (Vera-Ramirez et al., 2018). The same 
approach also appears encouraging for epithelial ovarian cancer, which has a high mortality rate 
following relapse (Pagotto et al., 2017). Ovarian cancer stem cells (CSCs) are a rare cellular 
population that exhibit high levels of basal macroautophagy and chemoresistance and are predicted 
to be a significant contributor to malignancy. Genetic ablation of ATG5 or pharmacological 
inhibition of autophagic flux significantly diminished the tumourigenic potential of CSCs in vitro 
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relapse in this scenario (Pagotto et al., 2017). Relevant links between autophagy and metastatic 
colon cancer have also emerged. Ragusa and colleagues identified a subset of cancer 
stem/progenitor cells, capable of PROX1-mediated metabolic adaptation in an autophagy-
dependant manner. These metabolic and autophagic changes in cancer cells appear to confer 
resistance to metabolic stress and promote their metastatic growth. Thus, inhibition of autophagy as 
part of combination therapy has been proposed as a strategy to attenuate the growth advantage of 
PROX1+ metastatic colon cancer cells (Ragusa et al., 2014). CMA and human cancer are also 
interconnected, with loss of LAMP-2A associated with attenuated tumourigenic potential (Kon et 
al., 2011; Thorburn and Debnath, 2011). 
 
A study by Karsli-Uzunbas et al. highlighted the challenges of broadly inhibiting autophagy in the 
clinic using a mouse model of KRAS driven-lung cancer, in which tumours developed before the 
systemic genetic ablation of Atg7 (Karsli-Uzunbas et al., 2014). In this context, autophagy 
inhibition by Atg7 whole body KO markedly decreased tumourigenesis in adult mice. Despite this 
elegant demonstration, these animals had reduced overall survival (two to three months) with an 
increased predisposition to bacterial infection and the onset of neurodegeneration (Karsli-Uzunbas 
et al., 2014). These data demonstrate that acute autophagy inhibition may be therapeutically 
beneficial in cancer, although several parameters (therapeutic window, drug safety, length of usage 
and drug site of action) will need to be carefully established to prevent secondary complications 
(Towers and Thorburn, 2016). This example also underscores the importance of developing 
targeted therapeutic strategies, which is particularly pertinent to post-mitotic tissues such as 
neurons, where autophagy is essential to sustain neural integrity. 
 
In healthy cells, autophagy is predicted to protect against malignant transformation by degrading 
toxic or superfluous cellular components (White, 2015). Nutrient deprivation is one of the best-
characterised signalling events known to induce macroautophagy (Laplante and Sabatini, 2012). In 
recent years, fasting and calorie restriction mimetics (e.g. hydroxycitrate) (Madeo et al., 2014) have 
garnered increased attention due to their reported influence on restricting cancer growth in vitro and 
in vivo (Pietrocola et al., 2016; Lee et al., 2012). In athymic mice with subcutaneous fibrosarcoma, 
a 48h starvation period or the use of calorie-restricted mimetics triggered an autophagy-dependent 
anti-cancer immune response. This beneficial effect was abolished when cancer cells were rendered 
autophagy-deficient upon Atg5 knockdown (Pietrocola et al., 2016). Autophagy-activating agents 
have also been demonstrated to improve the therapeutic response to multiple malignancies evolving 
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fasting may be infeasible or unsuitable for many patients, alternate nutrient restriction approaches 
with similar benefits may represent a more sustainable intervention (Nencioni et al., 2018). For 
example, selective restriction of non-essential dietary amino acids (serine and glycine) in 
combination with biguanide inhibition of mitochondrial respiration has been associated with 
enhanced survival in cancer-prone mice (Maddocks et al., 2017). Neoadjuvant metformin treatment 
in breast cancer patients undergoing chemotherapy has also been shown to induce a systemic 
metabolic profile akin to that observed in fasting (Cuyàs et al., 2019). Interestingly, metformin is 
also known to inhibit mitochondrial complex I (Wheaton et al., 2014). These distinct studies 
underscore a significant convergence upon mitochondrial metabolism in the context of cancer 
(Maddocks et al., 2017; Cuyàs et al., 2019). 
 
Autophagy is required for adult mice to survive nutrient deprivation, and its loss creates a catabolic 
dependence on nutrient stores, leading to metabolic imbalance (Karsli-Uzunbas et al., 2014). As this 
imbalance depletes essential nutrients from fat, muscle and liver, it has been postulated to reflect the 
cachexia commonly associated with cancer progression (Poillet-Perez and White, 2019). 
Interestingly, autophagy-deficient mice have recently been identified to have reduced circulating 
levels of the semi-essential amino acid arginine (Poillet-Perez et al., 2018). Many human tumours 
are arginine auxotrophs and derive arginine from the host to sustain metabolism, growth and 
function. Diminished levels of circulating arginine in autophagy-deficient mice impaired tumour 
growth, and could be partially reversed by dietary supplementation of arginine (Poillet-Perez et al., 
2018). Thus, host autophagic activity may sustain tumour growth via supplementation with 
necessary amino acids. Accordingly, in some instances, autophagy inhibition could represent a 
potential therapeutic strategy to restrict the bioavailability of certain nutrients and thus, 
tumourigenesis (Poillet-Perez and White, 2019). 
 
The precise mechanistic relationship between autophagy, fasting, FMDs and the potentiation of 
chemotherapeutic efficacy in human subjects is unclear (Caccialanza et al., 2019). Extensive large-
scale clinical studies are ultimately required to establish the efficacy of fasting and FMDs for cancer 
therapy (Caccialanza et al., 2019; Nencioni et al., 2019). It will also be essential to determine the 
parameters required to obtain the maximum benefit from FMDs and related interventions. Are these 
interventions beneficial for a majority of patients, or should they be selectively employed in a 
patient-specific fashion, i.e. depending on the patient profile, cancer type and stage? Furthermore, at 
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questions will be essential in harnessing the therapeutic potential of any autophagy-based 
intervention. 
 
A key challenge in the field is the development of clinical-grade diagnostics to monitor autophagy 
signalling in human patients. The capacity to rapidly assess autophagic status in clinical 
biospecimens will ultimately impact our physiological and mechanistic understanding of targeted 
treatments in this area and will be vital for shaping their evolution. Until these tools emerge, 
phenotypic profiling of patient-specific cancer subtypes may be a prerequisite to determine the 
value of autophagy modulation alongside ongoing treatment. Clinical trials aimed at uncovering 
cancer-specific autophagy biomarkers are underway and reviewed in (Levy et al., 2017a). 
 
An appraisal of the vast literature associated with modulating autophagy in cancer reveals a clear 
and unifying theme: it is a context-dependent process. Thus, the rigorous in vivo profiling of 
autophagy in relevant pre-clinical cancer models represents a distinct challenge for the field. 
 
4. Monitoring autophagy pathways in vivo: from bench to bedside  
 
Ultimately, implicating autophagy in any physiological system depends upon sensitive assays that 
can probe this process in a precise and cell-specific fashion. Our present-day understanding of these 
pathways in health and disease is ultimately due to continual advances in the development and 
refinement of tools to monitor autophagy using microscopy and biochemistry. We next outline 
critical developments in laboratory-based autophagy detection, with a view to the development of 
clinical diagnostics. 
 
4.1 Monitoring autophagy in the laboratory 
 
4.1.1 Macroautophagy 
Autophagy has been classically studied in cell culture using either metabolic or chemical stimuli. 
The most reliable readouts of autophagy are those based on converging data, e.g. monitoring 
autophagy flux of LC3 and p62 (and other autophagy associated factors) in the presence of the 
lysosomal vATPase inhibitor (e.g. Bafilomycin A1), and supported by fluorescence-based reporter 
assays or electron microscopy (the latter in the case of extreme phenotypes) (McWilliams and 
Ganley, 2019a). All of these assays have provided powerful insights into the mechanistic regulation 
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insights into autophagosome formation (Kuma et al., 2017). Immunodetection or GFP-labelling of 
N-terminal LC3 has enabled the visualisation of phagophores and autophagosomes in cells as 
puncta or ring-like structures (Kuma et al., 2017). Pioneering work from Noboru Mizushima and 
colleagues using GFP-LC3 transgenic reporter mice revealed that macroautophagy also proceeds at 
basal levels to varying degrees across all mammalian tissues (Mizushima et al., 2004). Numerous 
studies in "macroautophagy-deficient" mice support the physiological significance of these 
findings, where loss of basal macroautophagy via conditional tissue-specific genetic ablation of 
Atg5/7 has profound effects in mammals depending on the cell subtype affected, e.g. selective loss 
of autophagy in the nervous system results in severe neurodegeneration, whilst the selective loss of 
macroautophagy in liver cells results in systemic glucose dysregulation and the onset of 
tumourigenesis (Takamura et al., 2011; Komatsu et al., 2006).  
 
Such fluorescence-based reporter systems have enabled researchers across many fields to 
interrogate the physiological significance of macroautophagy in vivo. Observations using the GFP-
LC3 approach require validation with lysosomal inhibitors to reliably interpret and infer changes in 
autophagic flux. This control is necessary due to the acid labile properties of GFP, whose 
fluorescence becomes quenched in the acidic microenvironment of the lysosome. Such a validation 
approach is particularly challenging with rodent models, as the effects of lysosomal inhibitors in 
vivo are far more variable than under controlled in vitro conditions. Since the initial development of 
the GFP-LC3 reporter mice, other probe systems have emerged with different properties that enable 
the facile detection of autophagy in vivo without the use of inhibitors. These approaches exploit the 
acid-resistance properties of other fluorescent proteins, e.g. those in the red spectrum. To this effect, 
tandem reporter systems have emerged as powerful tools to monitor autophagy pathways in cells 
and tissues. Tandem reporters involve the use of red-green fusion proteins (e.g. mCherry-GFP) that 
can demarcate both autophagosomes and autolysosomes. In merged images using this approach, 
yellow structures represent autophagosomes, whereas mCherry-only puncta represent 
autolysosomes (due to the quenching of GFP). Consequently, when autophagosome-lysosome 
fusion is blocked, only the number of yellow puncta increases. This method has been successfully 
deployed in mice and includes the tandem fluorescent-tagged (TfLC3) reporter mouse model 
(mRFP-EGFP-LC3) and mCherry-GFP-LC3B reporter mice (McWilliams et al., 2018a; Kimura et 
al., 2007). 
 
Another complementary approach to track autophagic flux in vivo involves the GFP-LC3-RFP-
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LC3 and RFP-LC3ΔG. Ultimately, GFP-LC3 becomes degraded by autophagy and is quenched, 
whereas RFP-LC3ΔG remains stable (Kaizuka et al., 2016). Measurements of cellular GFP-
fluorescence intensity against total RFP-LC3ΔG fluorescence intensity provide a ratiometric 
readout of autophagic flux in cells and tissues. RFP-LC3ΔG cannot be lipidated due to the absence 
of c-terminal glycine, thus enhanced autophagy results in a decreased GFP:RFP ratio. Many of 
these tandem tag approaches have also been validated in Atg-null backgrounds (Kuma et al., 2017). 
As these reporter systems can measure basal autophagy in vivo without the need for validation by 
inhibitors, they provide a powerful way to clarify the contribution and importance of basal 
macroautophagy in healthy as well as neoplastic cells in vivo. For an excellent review of recent 
developments in this area, please consult (Kuma et al., 2017). 
 
4.1.2 Selective autophagy 
Damaged or defective cellular components can have deleterious effects on cellular function and 
viability. The sensing, identification and targeted destruction of such components can occur through 
selective autophagy. In this instance, damaged/defective cellular components become decorated 
with an "eat-me" signal (e.g. ubiquitin), and selectivity is conferred by cargo-specific receptors that 
engage the autophagy machinery (Rogov et al., 2014). Several receptors are associated with the 
selective autophagic degradation of a range of organelles, including mitochondria (mitophagy), 
peroxisomes (pexophagy), ferritin (ferritinophagy), endoplasmic reticulum (reticulophagy), nuclei 
(nucleophagy) and ribosomes (ribophagy). An excellent overview of these processes can be found 
in (Galluzzi et al., 2017a). 
 
Many of these selective autophagy pathways require detailed characterisation in vivo, and we have 
much to learn regarding their role in promoting or preventing tumourigenesis. We will focus on 
mitophagy due to recent advances in our molecular and physiological understanding of this process 
in tissues.  
 
 4.1.3 Focus on mitophagy 
Mitophagy is by far the most studied mode of selective autophagy in mammalian cells. For recent 
reviews on this topic, please consult (Palikaras et al., 2018; Rodger et al., 2018). At present, it 
seems that the term "mitophagy" was first used in a review by Scott and Klionsky in 1998 (Scott 
and Klionsky, 1998), and subsequently promoted by Lemasters in 2005 (Lemasters, 2005). The 
earliest description resembling our present-day understanding of mitophagy is the sequence of 
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green dye in tissue cultures, in the landmark cell biology studies of Margaret Reed Lewis and 
Warren Lewis (Lewis and Lewis, 1915). It is essential to recognise that the idea of monitoring 
mitochondrial turnover has captivated investigators over the past several decades. This is evidenced 
by extensive work from the 1950s-1970s using electron microscopy, which identified the presence 
of mitochondria inside lysosomes within a variety of mammalian tissues under steady-state 
conditions (Clark, 1957; Novikoff and Essner, 1962). Radiolabelling of mitochondrial proteins was 
also used as a surrogate assay to measure mitochondrial turnover (Fletcher and Sanadi, 1961).  
A revival of this research area occurred in 2008, with the demonstration that overexpression of the 
RBR E3-ubiquitin ligase Parkin in HeLa cells could drive dramatic levels of mitochondrial turnover 
(mitophagy) in response to chemical agents that dissipate mitochondrial membrane potential 
(Narendra et al., 2008). This critical proof-of-principle study established a new framework to 
investigate the selective turnover of mitochondria in tissue culture. It was subsequently elaborated 
by many laboratories that mitochondrial depolarisation stabilises and activates the mitochondrial-
associated ubiquitin kinase PINK1 (McWilliams and Muqit, 2017). Ultimately, the substrates of 
PINK1 are Parkin and ubiquitin, which are both phosphorylated at their respective Serine 65 
residues. Through a coordinated series of events, depolarised mitochondria become decorated in a 
coat of ubiquitin via feed-forward amplification signalling. "Mitochondrial ubiquitylation" serves as 
a potent signal for the recruitment of the autophagy machinery and the elimination of the damaged 
organelle. This stress-induced pathway has dominated the attention of researchers in the field of 
mitophagy, yet its role in mitochondrial elimination in vivo remained obscure until the advent of 
mitophagy reporter mice (Jang et al., 2018; Palikaras et al., 2018).  
 
Like fluorescent macroautophagy reporter mice that revealed a landscape of tissue-specific bulk 
degradation, the recent advent of mitophagy reporter systems and their corresponding mouse 
models have also redefined our understanding of mammalian mitochondrial destruction in vivo 
(McWilliams et al., 2016; Sun et al., 2015). The development of the mito-QC and mitochondrial 
Keima (mt-Keima) mouse models signified an important advance in the field of mitochondrial 
biology (McWilliams et al., 2016; Sun et al., 2015). Keima is a coral-derived pH-sensitive 
fluorescent protein, which can fluoresce in different wavelengths, depending on acidification state. 
In the mt-Keima mouse model, Keima is present in the mitochondrial matrix due to a COX8 
targeting sequence and emits green-fluorescence. A shift to red-fluorescence is observed upon 
mitophagic delivery to the lysosome (Sun et al., 2015). In the mito-QC mouse model, cytosolic 
mitochondrial networks are visible in yellow due to a tandem mCherry-GFP tag on the outer 
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2018a, 2016, 2018b). Upon delivery of mitochondria to the lysosome as in mitophagy, GFP 
fluorescence is quenched yet the mCherry signal remains stable. The aforementioned reporter 
systems provide a simple approach to measure mitophagy, and a related reporter system known as 
mito-Timer enables a temporal assessment of mitochondrial age and biogenesis in vivo (Wilson et 
al., 2019). The latter system exploits the fluorescence shift of DsRed1-E5 from green to red over 
time.  
 
As with any model, all systems have different strengths and limitations, but collectively these mice 
have facilitated a converging conceptual advance in our understanding of  mitophagy as a steady 
state process during mammalian development and disease (McWilliams and Ganley, 2019b; Jang et 
al., 2018; Palikaras et al., 2018; Kuma et al., 2017). Under steady state conditions, mitophagy 
appears to be a highly pervasive process with striking heterogeneity, even between cells of the same 
organ. These observations at steady state contrast dramatically with the notion of mitophagy as an 
induced stress response (Rodger et al., 2018; Palikaras et al., 2018; Jang et al., 2018). Furthermore, 
the demonstration that basal mitophagy is evolutionarily conserved from Drosophila to mammals 
using both mt-Keima and mito-QC is further evidence that suggests that the modulation of basal 
mitochondrial turnover is likely to be critical to tissue-specific homeostasis and metabolism (Lee et 
al., 2018; Sun et al., 2015; McWilliams et al., 2016). The idea that distinct basal and stress-evoked 
pathways orchestrate mitophagy in vivo is exemplified by the many demonstrations that basal 
mitophagy is unaffected in cells and tissues that lack a functional PINK1-Parkin signalling pathway 
(either PINK1 KO or Parkin Ser65 KI mutant mice) (McWilliams et al., 2018b; a). Consistent with 
this, subsequent data demonstrated that p62 (SQSTM1) is likely to play a crucial role in modulating 
basal mitophagy in vivo (Yamada et al., 2018).  
 
Much more work will be required to decipher the molecular determinants of basal mitophagy in 
vivo. Nonetheless, it is clear that many pathways likely operate to coordinate the elimination of 
defective or damaged mitochondria in a context-specific fashion (Rodger et al., 2018; Jang et al., 
2018; Palikaras et al., 2018). A significant challenge in the field will be to reconcile in vitro 
observations to in vivo pathophysiology. A step in this direction has emerged recently by Soutar 
and colleagues, who identified that the concentration of serum and more specifically albumin in 
tissue culture media had a potent influence on mitochondrial membrane potential and activation of 
the PINK1-Parkin pathway (Soutar et al., 2019). Higher albumin levels in FBS/FCS required 
greater concentrations of the protonophore carbonyl cyanide m-chlorophenylhydrazone (CCCP) to 











Long & McWilliams, 2019 
18 
However, this does not alter the depolarising effect of other agents known to activate this stress-
associated pathway (e.g. combined oligomycin and antimycin-A treatment) (Soutar et al., 2019). 
Such studies are particularly vital in the context of cancer biology, where recapitulating metabolic 
state is crucial for biological relevance (Voorde et al., 2019). It will be of considerable interest to 
determine the contribution of basal mitophagy to metabolic plasticity in cancer. 
 
Interestingly, aside from their role in modulating depolarisation-induced mitophagy in vitro, 
PINK1-Parkin signalling has long been linked with cancer biology. Indeed, Parkin has been 
proposed as a potential tumour suppressor (Bernardini et al., 2017; Veeriah et al., 2010). Links have 
also emerged between Parkin and glioblastoma via regulation of G1/S cyclins (Gong et al., 2014). 
In terms of tumour metabolism, loss of Parkin has been reported to drive the Warburg effect, a 
hallmark of many tumours (Zhang et al., 2011).  For an excellent review of Parkin signalling in 
oncology, please consult (Bernardini et al., 2017). Recently, a cullin RBR E3 ligase known as 
ARIH1 has been implicated in Parkin-independent mitophagy associated with protecting cancer 
cells from chemotherapy-induced cell death (Villa et al., 2017). Furthermore, prolonged mitotic 
arrest in cancer cells is associated with the induction of mitophagy, with AMPK and PFKFB3 
modulating the metabolic adaption and survival of cancer cells in this context (Doménech et al., 
2015). 
 
Mutations in PINK1 and Parkin are most known for their role in the neurodegenerative movement 
disorder, Parkinson's disease (PD) (Rodger et al., 2018; McWilliams and Muqit, 2017), yet the 
contribution of dysregulated mitophagy to PD pathology remains unclear. In terms of cancer 
biology, the inverse co-morbidity relationship between neurodegeneration and carcinogenesis is 
well known (Bajaj et al., 2010). However, an intriguing and somewhat overlooked point of 
convergence stems from epidemiological data demonstrating that PD patients have an increased risk 
of developing melanoma, but not other cancers (Bose et al., 2018; Ascherio and Schwarzschild, 
2016). Because defective macroautophagy is also associated with neuropathology (Menzies et al., 
2017), it will be interesting to investigate if this constitutes a pathogenic convergence point between 
these distinct disease states. 
 
In terms of modulating mitophagy in humans, Urolithin A (UA) has recently been reported to have 
metabolically-beneficial effects on mitochondrial function in humans (Andreux et al., 2019). 
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models (Ryu et al., 2016), it remains to be determined how UA administration influences 
mitophagy signalling in human tissues. 
 
 
4.2 Monitoring autophagy pathways in the clinic 
 
Despite significant advances in the experimental monitoring of macroautophagy and selective 
autophagy, there is still a long road to travel before reliable diagnostics can infer meaningful 
information about these cellular processes in the clinic. Autophagy is a context-specific process 
with different effects dependent upon cell and cancer type. Accordingly, the diagnostic value of 
measuring autophagy pathways in clinical specimens is advantageous for discovery science, but of 
limited use to clinical diagnostics at present (Galluzzi et al., 2017b). Many caveats exist with the 
current methods to monitor autophagy pathways, including the need to monitor flux as opposed to 
the level of LC3 lipidation. Furthermore, methods of measuring these can vary dramatically from 
laboratory to laboratory, and LC3 levels can also differ across samples. The emerging landscape of 
selective autophagy pathways indicates a growing need to identify pathway-specific receptors. Even 
more sensitive reporter systems will also be required to discriminate between these processes both 
in vitro and in vivo. Such developments will be essential to resolve the contribution of selective 
autophagy or macroautophagy pathways to a given cancer subtype.  
 
In order to effectively develop autophagy-specific therapies for the clinic, it will be essential to 
standardise longitudinal measurements of autophagy across many laboratories. Significant efforts in 
the global autophagy community are already underway to do this (Klionsky et al., 2016; Galluzzi et 
al., 2017a). Given the vast mechanistic heterogeneity in cancer cell biology, distinct autophagy-
related biomarkers will likely emerge that are suitable for subsets of particular cancers. It will be 
exciting to determine the predictive and prognostic value of such autophagic signatures in the 
context of cancer predisposition, progression and chemoresistance. 
 
5. Summary and future outlook 
 
It is difficult to generalise a single role for autophagy in cancer, as this multistep process can confer 
survival advantages to both tumour and host. More than any other disease field, cancer biologists 
have embraced complexity and recognised the context-dependent nature of autophagy and its 
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where the development of precision therapeutics that drive or diminish autophagy signalling in 
defined contexts could provide a clinically meaningful benefit for cancer patients. The rigorous and 
sensitive profiling of autophagy in well-controlled pre-clinical models will undoubtedly contribute 
towards achieving this goal. 
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Figure 1: Generalised overview of mammalian macroautophagy 
Macroautophagy is a conserved process that degrades a variety of different types of cellular cargo 
in a non-selective fashion, ranging from protein aggregates to defective organelles and even 
intracellular pathogens. Autophagosome biogenesis involves crosstalk between various organelles. 
Many organellar compartments (ER, Golgi complex, endosomes, and mitochondria) have been 
shown to contribute to the phagophore, and the resultant autophagosome. Mature autophagosomes 
are often juxtaposed to multiple smaller vesicles as depicted here. Following the encapsulation of 
cargo, autophagosomes undergo fusion with acidic compartments of the cellular endolysosomal 
system. The fusion of autophagosomes with lysosomes generates the terminal compartment of the 
autophagy pathway: the autolysosome, required for the completion of autophagy. However, when 
macroautophagy and endocytosis converge, late endosomes can fuse with autophagosomes to 
generate an amphisome. Created with BioRender.  
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